Running counts from FDA, the SEC, ClinicalTrials.gov and our own deal reporting. Each page says what is counted, what is left out, and links every record to its source.
Disclosed funding across 31 venture rounds, IPOs and private placements reported since Oct. 1. We also reported 15 acquisitions; those priced in dollars total $12.1B.
FDA cleared 293 devices through the 510(k) pathway in October 2026, 8% fewer than the month before. The busiest review panels were orthopedic (42), general, plastic surgery (40), cardiovascular (34).
94 health-care companies reported selling $839M in private offerings on new Form D filings in the past 30 days. By industry: other health care 43, biotechnology 40, pharmaceuticals 7, hospitals and physicians 3, health insurance 1.
Companies registered 266 new Phase 2 or Phase 3 interventional trials on ClinicalTrials.gov in the past 30 days, 117 of them Phase 3.
The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.